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Comparison of broad-spectrum antibiotics and 
narrow-spectrum antibiotics in the treatment of lower 
extremity cellulitis
Introduction
Skin and soft tissue infections (SSTIs) are classified based on 
the presence or absence of purulence; they are further divided 
based on severity and complexity.[1] Cellulitis is an infection 
of deep dermis and subcutaneous tissues characterized 
by swelling, erythema, pain, and tenderness.[2] A recent 
analysis of emergency department (ED) visits for SSTIs by 
the National Hospital Ambulatory Medical Care Survey for 
1993–2005 concluded that there is nearly a 3-fold increase in 
the incidence of SSTIs.[3] Pathogens are typically skin flora 
with the most common causative pathogens being Group A 
β-hemolytic Streptococcus and Staphylococcus aureus.[2,4] 
Community-acquired methicillin-resistant Staphylococcus 
aureus (MRSA) has become increasingly prevalent such that 
it is included in the differential for causative pathogens.[5] 
Nevertheless, the current Infectious Diseases Society of America 
(IDSA) guidelines recommend that non-purulent cellulitis be 
treated with antibiotics active against methicillin-sensitive 
Staphylococcus aureus (MSSA) and β-hemolytic Streptococci 
only.[1] Broad-spectrum antibiotics are recommended only in 
immunocompromised patients or patients with systemic signs 
of illness.[1] The guidelines define systemic signs of illness 
as the presence of two or more of the systemic inflammatory 
response syndrome (SIRS) criteria. However, broad-
spectrum antibiotics continue to be administered for patients 
with uncomplicated SSTIs.[6-8] Antimicrobial resistance is 
considered a growing problem worldwide. The increased use 
of anti-pseudomonal antibiotics has been linked to increased 
risk of multidrug-resistant organisms.[9] It is also important 
to mention that the risk of MRSA infections is increased in 
IV drug users, prisoners, children and those with penetrating 
trauma, and purulent drainage.[3]
The recommended duration of the treatment for uncomplicated 
cellulitis is 5 days of antimicrobial therapy, which has been 
shown to be as effective as a 10-day course.[1,8,10] Several 
studies have found that cellulitis treatment failure was not 
different regardless of the spectrum of activity.[6,11] Data 
are robust that non-purulent cellulitis can be treated with 
non-MRSA antibiotics such as penicillin or first-generation 
cephalosporins.[1,6] The purpose of this study was to determine 
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the treatment failure rate of lower extremity cellulitis 
when treated with broad-spectrum antibiotics compared to 
narrow-spectrum antibiotics and to describe the inappropriate 
use of broad-spectrum antibiotics in lower extremity cellulitis.
Methods
Study design, data source, and data collection
A retrospective chart review of adult patients 18 years or 
older who were admitted to the hospital or visited the ED 
between January 2016 and May 2016 was conducted. Patients 
were identified using International Classification of Diseases, 
10th revision. Patients were included only if they had a lower 
extremity cellulitis diagnosis (L03.115, L03.116, and L03.90). 
The primary author reviewed charts to select eligible patients 
for review of the electronic record. Patient’s demographics, 
laboratory and microbiological results, and antibiotics 
administered during admission or prescribed were reviewed and 
recorded [Table 1]. Patients were excluded if they had one or 
more of the following: Upper extremity cellulitis; complicated 
SSTIs; animal bites; immunosuppression; purulent cellulitis; 
surgical site infections; IV drug use; pregnancy; separate 
or concomitant source of infection; and history of MRSA 
infection. Immunosuppression was defined as neutropenia 
and immunosuppressive therapy (e.g., chemotherapy in 
the past 4 weeks, cyclosporine, tacrolimus, azathioprine, 
20 mg/day or more of prednisone, or its equivalent for more 
than 3 months).[12] Sample size was determined based on the 
findings of previous studies.[6-8,13] This study was deemed by 
Northwest Medical Center Institutional Review Board.
Definitions
Diagnosis of cellulitis was confirmed through chart review based 
on the provider’s assessment and documentation for cellulitis. 
Complicated SSTIs were defined as infections that extend 
deeper into tissues other than skin and subcutaneous tissues 
including necrotizing fasciitis and diabetic foot infections.[14] 
Due to the lack of consensus definition,[14] we defined broad 
spectrum as antibiotics with activity against Pseudomonas 
aeruginosa or a combination of two injectable antibiotics with 
different spectrum of activity.[6,8,11] Any antibiotic administered 
or prescribed for lower extremity cellulitis during the study 
was considered in the analysis. Treatment failure was defined 
as any repeat visit to the hospital due to cellulitis. ED visit 
only without admission also was included in this definition. 
Duration of therapy was defined as the cumulative number 
of calendar days during which antibiotics were administered 
and/or prescribed. Duration of therapy longer than 10 days 
was considered inappropriate.[6,11] Inappropriate antibiotic 
use was defined as the use of vancomycin in the absence of 
penicillin allergy, and the use of piperacillin-tazobactam (PTZ) 
in the absence of indication (i.e., SIRS criteria).[1] SIRS was 
defined as the presence of two of the following: Heart rate 
>90 beats/minutes, respiratory rate >20/min, white blood cell 
count (WBC) >12,000/mm3, or <4,000/mm3, or >10% bands, 
and body temperature >38°C or <36°C.
Outcomes assessment
Treatment failure in patients treated with narrow-spectrum 
antibiotics compared to broad-spectrum antibiotics was 
considered as the primary outcome. Cumulative duration of 
therapy, hospital length of stay, and inappropriate antibiotic use 
in hospitalized patients were considered secondary outcomes.
Means and standard deviation were calculated for continuous 
variables. Frequency and percentage were reported for the 
categorical variables. Chi-square and Student’s t-test were used 
to evaluate the primary and secondary outcomes, respectively. 
Table 1: Demographic characteristics for those who received (broad- and narrow-spectrum antibiotics)
Variable Broad‑spectrum antibiotics (n=27) Narrow‑spectrum antibiotics (n=93) P‑value
Age (mean, SD) 68 (19) 59 (23) 0.06
Hospital admission n (%) 27 (100) 18 (19.3) 0.05
Sex n (%) 0.068
Female 10 (37) 53 (56)
Male 17 (62) 40 (43)
BMI, Kg/m2 (mean, SD) 31.2 (1) 30.5 (1) 0.69
Temperature, °F, (mean, SD) 99 (1) 98 (0.7) 0.001
WBC (mean, SD) 10.71 (5.8) 7.4 (2) 0.006
MRSA nasal -
Positive 2 0
Negative 7 4
N/A 18 89
Lactic acid ≥2 (n)* 4 0 0.001
SIRS+n (%) 6 (22) 1 (1) -
SD: Standard deviation, BMI: Body mass index, WBC: White blood cell count 109 cell/L, °F: Fahrenheit, MRSA: Methicillin-resistant Staphylococcus aureus, SIRS: Systemic inflammatory response 
syndrome, *Only four patients had lactic acid levels ≥2 in the broad-spectrum antibiotics
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Independent risk factors for hospital repeat visit were identified 
by logistic regression analysis. Variables with P = 0.05 or less 
were included in multivariate logistic regression analysis. 
STATA 14.0 (Stata Corp, College Station, TX) software was 
used for data analysis.
Results
A total of 599 patients were identified with a diagnosis of 
cellulitis between January 2016 and May 2016, of which 
479 (79.9%) were excluded from the analysis after applying 
our inclusion and exclusion criteria [Figure 1]. The final cohort 
included 120 patients with lower extremity cellulitis [Figure 1]. 
Among the 120 included patients, 93 (77.5%) have received 
narrow-spectrum antibiotics and 27 (22.5%) have received 
broad-spectrum antibiotics. Demographics, laboratory, and 
microbiological values are shown in Table 1. Only 18 (19.3%) 
of those who received narrow-spectrum antibiotics were 
hospitalized and received injectable antibiotics compared 
to 27 (100%) who received broad-spectrum antibiotics 
(P = 0.05). The WBC was significantly higher among those 
who received broad-spectrum antibiotics (10.7 × 109 cell/L 
± 5.8) compared those who received narrow-spectrum 
arm (7.4 × 109 cell/L ± 2) (P = 0.006). 4 patients (14.8%) 
had elevated lactic acid (i.e., ≥2 mmol/L) levels in the broad-
spectrum group, while none of the patients in the narrow-
spectrum group had elevated lactic acid (P = 0.001). Of the 
four patients, two had other reasons for lactic acid elevation 
in addition to cellulitis (i.e., rhabdomyolysis and missing 
hemodialysis session). SIRS was present in 6 of 27 (22%) 
patients in the broad-spectrum group compared to 1 of 18 (1%) 
in the injectable narrow-spectrum group [Table 1]. The most 
commonly used antibiotic in the broad-spectrum arm was PTZ 
17 of 27 (62.9%), among which only 1 of 17 (5.8%) patient 
met SIRS criteria [Table 2]. Vancomycin in combination with 
PTZ was used in 13 of 27 (48.1%) patients, among which 
only 1 of 27 (7.6%) was positive for MRSA [Table 2]. The 
most commonly used antibiotics in the narrow-spectrum arm 
were cephalexin 48 (51.6%), sulfamethoxazole-trimethoprim 
23 (24.7%), clindamycin 21 (22.5%), vancomycin 8 (8.6%), 
and cefazolin 5 (5.3%). MRSA nasal screening was performed 
in only 4 (4.3%) patients in the narrow-spectrum arm and none 
tested positive [Table 2]. Only 1 of 27 (3.7%) patient had a 
positive blood culture in the broad-spectrum arm. Yet, only 
15 of 27 (55.5%) had blood samples collected for culture. 
13 (48%) patients in the broad-spectrum arm had an all-cause 
repeat visit compared to 19 (20%) in the narrow-spectrum 
arm (OR: 3.47, [95% CI: 1.36–8.8]). 1 patient (4%) in the 
broad-spectrum arm had hospital repeat visit due to cellulitis 
compared to 3 (3%) in the narrow-spectrum arm (P = 0.89) 
[Figure 2].
Univariate logistic regression analysis revealed that the length 
of stay (OR: 1.36, [95% CI: 1.15–1.62]) and body temperature 
(OR: 1.5, [95% CI: 1–2.38]) were statistically associated 
with repeat visit [Table 3]. However, after adjusting for 
confounders in the multivariate logistic regression Table 4, 
only the length of stay was associated with higher odds for 
repeat visit (OR: 1.32, [95% CI: 1–1.6]). The mean duration 
of therapy was not different between the groups: 9.3 ± 2 days 
in the broad-spectrum arm compared to 8.3 ± 2 days in the 
narrow-spectrum arm (P = 0.19). 27 patients received more 
Figure 1: Patient selection flowchart
Figure 2: Primary outcome
Table 2: Injectable antibiotics used among patients who received 
broad- and narrow-spectrum antibiotics
Antibiotics, Naf SIRS, N MRSAa, N Penicillin 
allergy, N
Vancomycin (30) Positive (7) Positive (1) Positive (2)
PTZ (17) Positive (1) Positive (1) -
Vancomycin+PTZ (13) Positive (1) Positive (1) -
Meropenem (1) Positive (1) N/A Positive (1)
Cefazolin (8) Negative (8) Negativeb (3) -
Ceftriaxonec (8) Positive (1) Positivec (1) -
Cefoxitind (3) Positive (2) Negative (2) -
Levofloxacin (1) Positive N/A Positive (1) 
Ampicillin-sulbactam (1)e Negative Positive -
aOnly 13 patients had MRSA nasal screen done in both arms, N/A: Not available, bOnly three 
patients had MRSA nasal screen done in both arms, cMRSA nasal screen was done in two 
patients, patient also was on vancomycin, dAll received vancomycin as well, and MRSA nasal 
screen was done in two patients only, ePatient was also on clindamycin, fPatients could receive 
combination of antibiotics at the same time
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than 10 days of total antibiotic therapy 27 of 120 (22.5%) in 
both arms. The mean length of stay was similar between the 
broad-spectrum group and narrow-spectrum group (4.6 ± 2 vs. 
4.1 ± 1 days, P = 0.29), respectively.
Discussion
Cellulitis is a commonly encountered SSTI. The total number 
of SSTIs related visits to ambulatory care physicians increased 
from 8.6 million in 1997 to 14.2 million in 2005.[11] Despite 
the availability of national guideline, uncomplicated cellulitis 
is commonly treated with broad-spectrum coverage.[7,8,15] Few 
patients had systemic signs of illness (i.e., SIRS) and the 
majority of patients in the broad-spectrum arm (77.8%) 21 of 
27 did not need such broad coverage.[1] This is contradictory to 
the most recent IDSA guidelines and consistent with previous 
studies demonstrating that broad-spectrum antibiotics were 
overutilized in patients with uncomplicated SSTIs.[6,8,15] 
Havey et al. found thatthe PTZ use was deemed inappropriate 
for 86.7% of patients with cellulitis, 66.7% of patients with 
abscess.[13] In their retrospective study, Jenkins et al. included 
533, of which 320 (60%) patients diagnosed with non-purulent 
cellulitis. Blood cultures were collected from 225 of 320 (70%) 
patients and only 15 (5%) had positive blood cultures. Not 
surprisingly, Gram-negative organisms were identified only 
in 1 (2%) patient. Nevertheless, 144 of 320 (45%) patients 
received broad-spectrum antibiotics.[6] This study shares some 
similarities with their studies in that the use of antipseudomonal 
antibiotics (i.e., PTZ in our study) was commonly administered 
17 of 27 (62.9%) with only 6 patients (22%) meeting SIRS 
criteria [Table 2]. Jenkins et al. conducted another retrospective 
pre-intervention-post-intervention study.[7] They found that 
the exposure to antibiotics with antipseudomonal activity 
decreased from 28% to 18%. Based on their findings, the 
development of guidelines seems to be an attractive solution to 
decrease the inappropriate use of broad-spectrum antibiotics. 
Walsh et al. reported the inappropriate use of antibiotics in 
SSTIs without complicating factors.[8] They reported that 21 
of 163 (17.5%) received antipseudomonal coverage. Only 
3 (6.4%) Gram-negative organisms were isolated from wound 
cultures.
Altogether, we think that our use of broad-spectrum antibiotics 
in non-purulent cellulitis is not justified given our clinical 
and laboratory findings. Because we excluded patients with 
complicated SSTIs, active IV drug users, patients with a history 
of MRSA infection, and purulent cellulitis, vancomycin use 
was considered inappropriate in 23 of 30 (76.6%), as only two 
patients had documented penicillin allergy and only nine had 
an MRSA nasal screening done of which two had SIRS on 
admission [Table 2]. In our institution, MRSA nasal screening 
is frequently done in the intensive care unit (ICU) only and will 
not be done for patients admitted to the medical floor unless 
ordered by the provider. MRSA nasal screening was done in 
13 (10.8%) patients in both arms [Table 2]. Controversy exists 
with regard to the utility of MRSA surveillance in hospitalized 
patients.[13] One study found that MRSA colonization 
increases the risk of MRSA infection.[16] Safdar et al. 
conducted a systematic review to determine the relationship 
between MRSA or MSSA carriage status and subsequent 
infection.[17] They found that patients colonized with MRSA 
had 4-fold increased risk for MRSA infection compared to 
MSSA-colonized patients (OR: 4.08, [95% CI, 2.09–7.94]). 
In addition, IDSA guidelines recommend the addition of 
vancomycin or other antibiotics with activity against MRSA 
in patients colonized with MRSA.[1]
The mean duration of therapy in our study was similar in both 
arms (9.3 vs. 8.3 days) in the broad-spectrum arm and narrow-
spectrum arm, respectively. Our study showed that the majority 
of our cellulitis patients 96 of 120 (80%) received treatment of 
10 days or less, with only 24 of 120 (20%) receiving antibiotics 
of >10 days. This was surprising as our expectation was that the 
majority of patients will receive antibiotic therapy for 14 days 
or more as this was commonly reported in previous studies.[6,8] 
IDSA guidelines recommend duration with antimicrobial 
therapy for 5 days, but longer duration of therapy may be 
needed in patients who showed evidence of delayed response. 
Hepburn et al. conducted a randomized, double-blind placebo-
controlled trial to determine if 5 days of therapy provided equal 
efficacy to 10 days of therapy.[10] They found that the resolution 
of signs of infection was similar between both groups. The 
authors of this study used Levofloxacin as the drug of choice 
of this study and generalizing results to different antibiotics 
may not be applicable. Jenkins et al. in his retrospective pre-
intervention-post-intervention study also found that patients 
who received a short course of therapy were not more likely 
to experience clinical failure than those who received a longer 
course of therapy.[6]
This study has several limitations. First, this was a retrospective 
study and we could only control for confounders that we 
Table 3: Univariate regression analysis clinical associations for 
repeat visit
Variable Odds ratioa P value* 95% confidence interval
Age 1.00 0.31 0.99–1.0
Sex 0.43 0.05 0.18–0.99
BMI 1.00 0.10 0.99–1
Length of stay 1.36 <0.001 1.15–1.62
Temperature 1.5 0.02 1–2.38
SIRS 4.00 0.08 0.85–19
WBC 1.00 0.14 0.9–1.12
BMI: Body mass index, SIRS: Systemic inflammatory response syndrome, WBC: White blood 
cell count, a: Odds ratio greater than one was considered significant, *P≥0.05 was considered 
statistically significant
Table 4: Multivariate logistic regression model for repeat visits 
after adjusting for the other confounders
Variable Odds ratio P value 95% confidence interval
Length of stay 1.32 0.024 1–1.6
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collected. Second, also due to the retrospective nature and the 
absence of blinding, there could be a chance for reviewer bias; 
however, we tried to avoid bias during data collection through 
extensive chart review and excluding patients with questionable 
non-purulent cellulitis. Third, due to the retrospective nature of 
this study, we did not evaluate delayed response and the need 
for antibiotics for more than 5 days, or previous antibiotic use 
before admission or ED visits. This is important as the most 
recent IDSA guidelines recommend to broaden the antibiotic 
coverage in patients who fail oral therapy. Fourth, severity of 
illness may not have been captured well in patient’s charts. 
Fifth, using repeat visit as the only criterion for treatment, 
failure may be insufficient and a closer follow-up and patient 
contact should have been implemented for better evaluation of 
the clinical outcomes. Sixth, the relatively small sample size 
in the broad-spectrum treatment arm could have affected the 
results of this study; however, it is comparable to the previous 
studies addressed the same problem. Last, we used SIRS 
criteria to determine the need for broad-spectrum antibiotics 
in patients with uncomplicated cellulitis. This is consistent 
with IDSA guidelines;[1] nevertheless, the task force of the 
Society of Critical Care Medicine considered SIRS criteria to 
be unhelpful in identifying sepsis.[17] This was supported by a 
study conducted in Australia and New Zealand that found one 
in eight patients admitted to ICUs with infection and organ 
failure did not fulfill the minimum two or more SIRS requisite 
to be labeled with sepsis diagnosis.[18]
In conclusion, the use of broad-spectrum antibiotics in 
patients with uncomplicated SSTIs is common and is not 
recommended based on the results of our study. We believe that 
implementation of clinical practice guidelines and providing 
frequent reminders to providers to adhere to national clinical 
guidelines will help in reducing the unnecessary use of broad-
spectrum antibiotics.
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